autologous human tumor-derived HSPPC-96

DRUG3 trials

Sponsors

Agenus Inc.

Conditions

Lymphoma, FollicularLymphoma, Small LymphocyticRenal Cell Carcinoma

Phase 2

A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

CompletedNCT00081809

Agenus Inc.Lymphoma, Follicular, Lymphoma, Small Lymphocytic

Start: 2000-03-31End: 2005-06-30Target: 35Updated: 2023-09-28

Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma

TerminatedNCT00082459

Agenus Inc.Renal Cell Carcinoma

Start: 2002-07-31End: 2005-12-31Target: 40Updated: 2012-09-07

Phase 3

Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer

CompletedNCT00033904

Agenus Inc.Renal Cell Carcinoma

Start: 2000-06-30End: 2007-04-30Target: 650Updated: 2012-09-07

Related Papers

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.

2008-07-03232 citations